Standing Order
Recursion Pharmaceuticals, Inc.

Dashboard

Recursion Pharmaceuticals, Inc.

RXRXNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$2.0B
Price$3.7052w $2.84 – $6.79
Conviction3/ 5
Revenue (TTM)$55M
Revenue growth YoY-14.9%
P/E (trailing)—
Gross margin-46.7%
Operating margin-991.7%
Net margin-945.9%
52w price change-15.3%
Next earningsNov 4, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Sep 21
    DealSEC

    8-K item 1.01: entered into material definitive agreement.

  • Sep 16
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Sep 10
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Sep 2
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Aug 18
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Aug 18
    Ownership changeSEC

    Form 4 insider ownership change filing dated 2026-08-18.

  • Aug 18
    Ownership changeSEC

    Form 4 filing reporting change in beneficial ownership by insider at Recursion Pharmaceuticals.

  • Aug 13
    Trial initiationClinicalTrials.gov

    Exscientia (Recursion subsidiary) initiates Phase 1 dose-finding trial of EXS73565 in relapsed/refractory B-cell malignancies (NCT06980116, recruiting).

  • Aug 13
    Trial initiationClinicalTrials.gov

    Recursion subsidiary Exscientia updates NCT05985655 Phase 1/2 trial of GTAEXS617 in advanced solid tumors to recruiting status.

  • Aug 6
    Ownership changeSEC

    Form 4 insider transaction filing

  • Aug 5
    Financial resultsSEC

    8-K filing (items 2.02, 7.01, 9.01) disclosing financial results for RXRX.

  • Jul 9
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 2
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 2
    Ownership changeSEC

    Form 4 insider transaction filing by RXRX.

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 22
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing for RXRX.

Not financial advice — research and opinion only. Disclosures